Clinical trials: Adrenocortical Tumor
Adrenocortical Carcinoma
Studying Genes in Samples From Younger Patients With Adrenocortical Tumor
RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01528956
- Testing
- DNA methylation analysis, RNA analysis, gene expression analysis
- Volunteers
- 10 people
- Sponsor
- Children's Oncology Group
Aldosterone-Producing Adenoma
CXCR4 Targeted PET Imaging in APA Preoperative Localization Diagnosis
The goal of this clinical trial is to evaluate the effectiveness of CXCR4 targeted PET imaging in preoperative localization diagnosis of primary aldosteronism (PA).
- Trial name
- NCT05839483
- Testing
- CXCR4
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhongnan Hospital
Mild Autonomous Cortisol Secretion, Autonomous Cortisol Secretion (ACS)
Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)
The purpose of this study is to evaluate the safety and tolerability of 1 mg osilodrostat therapy in patients with mild autonomous cortisol secretion (MACS), and to determine the impact on 24h urine steroid metabolome and…
- Trial name
- NCT07104812
- Testing
- Osilodrostat 1 MG
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
Cushing Syndrome, Adrenocortical Carcinoma
Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma
Adrenocortical Carcinoma (ACC) is an extremely rare disease. Approximately 50% of ACC in adults are functioning leading to hormonal and metabolic syndromes.
- Trial name
- ABACUS (NCT03145285)
- Testing
- Abiraterone Acetate
- Where
- Italy
- Volunteers
- 10 people
- Sponsor
- Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Hypertension
Omics Signature in the Diagnosis of Hypertension
The purpose of this study is to assess the validity and usefulness of omics signatures for improved identification and risk stratification of patients with endocrine hypertension and stratification of patients with primary…
- Trial name
- ENSAT-HT (NCT02772315)
- Testing
- omics
- Where
- 5 sites in France, Italy and 2 more
- Volunteers
- 4,000 people
- Sponsor
- Radboud University Medical Center
Locally Advanced Adrenal Cortical Carcinoma, Metastatic Adrenal Cortical Carcinoma
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
This phase II trial compares the effect of giving cabozantinib with or without cemiplimab in patients with adrenocortical cancer that has spread to nearby tissue or lymph nodes (locally advanced), and that cannot be removed by…
- Conditions
- Locally Advanced Adrenal Cortical Carcinoma, Metastatic Adrenal Cortical Carcinoma, Recurrent Adrenal Cortical Carcinoma, Stage III Adrenal Cortical Carcinoma AJCC v8
- Trial name
- NCT06900595
- Testing
- Biospecimen Collection, Cabozantinib, Cemiplimab
- Where
- 81 sites in United States
- Volunteers
- 48 people
- Sponsor
- National Cancer Institute (NCI)
Type 2 Diabetes, Cortisol Excess
Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)
CAPTAIN-T2D will take place in two parts. Part 1 (Screening) will evaluate patients with type 2 diabetes and elevated cortisol risk factors for trial eligibility and the presence of elevated cortisol.
- Trial name
- CAPTAIN-T2D (NCT07296484)
- Testing
- clofutriben
- Where
- 61 sites in United States
- Volunteers
- 1,500 people
- Sponsor
- Sparrow Pharmaceuticals
Radiotherapy, High-risk Localized Adrenocortical Carcinoma
A Prospective, Randomized, Multicenter Clinical Study Comparing Adjuvant Radiotherapy Versus Observation in High-risk Localized Adrenocortical Carcinoma After Surgery.
This study is a prospective, randomized, controlled, multicenter clinical trial designed to evaluate whether adjuvant radiotherapy can improve the 3-year recurrence-free survival (RFS) in high-risk localized adrenocortical…
- Trial name
- NCT07141147
- Testing
- Radiation
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Sun Yat-sen University
Cushing Syndrome, Hypercortisolism
Nailfold Capillaroscopy Evaluation in Cushing Syndrome Patients
This cross-sectional, single-center study will assess the microvascular function using a nailfold video-capillaroscopy in patients with endogenous Cushing syndrome.
- Trial name
- NCT04433819
- Where
- Turkey (Türkiye)
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Marmara University
Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma
Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
The goal of this open-label randomized, multicenter, comparative phase II trial is to evaluate the efficacy of the immunotherapy, dostarlimab, as first-line treatment for deficient mismatch repair (dMMR)/microsatellite…
- Conditions
- Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma, Neuroendocrine Carcinoma
- Trial name
- Pan-MSI-ACSE (NCT06333314)
- Testing
- Dostarlimab, Chemotherapy
- Where
- 22 sites in France
- Volunteers
- 120 people
- Sponsor
- UNICANCER
Adenovirus, Anesthesia
Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
Understudied drugs will be administered to children per standard of care as prescribed by their treating caregiver and only biological sample collection during the time of drug administration will be involved.
- Conditions
- Adenovirus, Anesthesia, Anxiety, Anxiolysis
- Trial name
- PTN_POPS (NCT01431326)
- Testing
- The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:
- Where
- 52 sites in United States, Canada and 3 more
- Volunteers
- 3,520 people
- Sponsor
- Daniel Benjamin
Adrenal Cortical Carcinoma, Adrenal Cortical Cancer
Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma
Adrenocortical carcinoma (ACC) is a rare aggressive malignant tumor. According to the literature, the 5-year survival rate of ACC is 12%-47%.
- Conditions
- Adrenal Cortical Carcinoma, Adrenal Cortical Cancer, Adrenal Cancer
- Trial name
- NCT06831175
- Testing
- Camrelizumab, Apatinib, mitotane
- Where
- China
- Volunteers
- 28 people
- Sponsor
- West China Hospital
Adrenal Gland Neoplasms
Towards an Easy-to-use Adrenal Cancer/Tumor Identity Card
Malignant pheochromocytoma/paraganglioma (MPP) and adrenocortical carcinoma (ACC) are two rare cancer entities with a very unfavorable prognosis.
- Trial name
- COMETETACTIC (NCT02672020)
- Testing
- omics identity card
- Where
- 21 sites in France
- Volunteers
- 448 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hypertension, Hypercortisolemia
Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome
Osilodrostat has proven to be a safe and efficacious treatment for patients with CS. Demonstrating normalisation of hypercortisolaemia and in patients with hypertension and/or dysglycaemia clinically relevant and statistically…
- Conditions
- Hypertension, Hypercortisolemia, Cushing Syndrome
- Trial name
- LINC CARE (NCT07247162)
- Testing
- Osilodrostat
- Where
- 3 sites in United States
- Volunteers
- 63 people
- Sponsor
- RECORDATI GROUP
Mild Autonomous Cortisol Secretion (MACS), Autonomous Cortisol Secretion (ACS)
Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS
single-center, randomized, double-blind, placebo-controlled Phase 2 study to evaluate safety and efficacy of overnight metyrapone in patients with MACS.
- Trial name
- NCT07138274
- Testing
- Metyrapone 250 mg Oral Tablets
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Mayo Clinic
Rare Diseases, Amyloidosis
Institutional Registry of Rare Diseases
The goal of this observational study is to create a single macro registry system with data collection on common clinical features, grouping the different rare diseases (RD).
- Conditions
- Rare Diseases, Amyloidosis, Sarcoidosis, Phacomatosis
- Trial name
- NCT06573723
- Where
- Argentina
- Volunteers
- 380 people
- Sponsor
- Hospital Italiano de Buenos Aires
Adrenal Tumor, Pheochromocytoma
Randomized Clinical Trial of Posterior Retroperitoneoscopic Adrenalectomy Versus Lateral Laparoscopic Adrenalectomy
Laparoscopic adrenalectomy has become the gold standard operation for non-malignant adrenal tumors replacing open adrenalectomy.
- Conditions
- Adrenal Tumor, Pheochromocytoma, Conn's Syndrome, Cushing's Syndrome
- Trial name
- NCT01959711
- Testing
- Posterior RA, Lateral transperitoneal LA
- Where
- Poland
- Volunteers
- 65 people
- Sponsor
- Jagiellonian University
Acinar Cell Carcinoma, Adenoid Cystic Carcinoma
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may…
- Conditions
- Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma, Adrenal Gland Pheochromocytoma
- Trial name
- NCT02834013
- Testing
- Biospecimen Collection, Computed Tomography, Echocardiography Test
- Where
- 1,007 sites in United States, Guam
- Volunteers
- 798 people
- Sponsor
- National Cancer Institute (NCI)
Adrenal Disease
Comparison Between Posterior Retroperitoneoscopic Adrenalectomy and Laparoscopic Adrenalectomy
The purpose of this study is to compare two surgical methods of adrenalectomy. One is called PRA(posterior retroperitoneal adrenalectomy), which is performed through 3 or 4 holes at patient's back.
- Trial name
- PRA (NCT01676025)
- Testing
- PRA, LA
- Where
- South Korea
- Volunteers
- 83 people
- Sponsor
- Seoul National University Hospital
Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion
SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome
This is a randomized, placebo-controlled, study of SPI-62 in subjects with ACTH-dependent Cushing's syndrome caused by a non-adrenal tumor.
- Conditions
- Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion, Cortisol Excess, Cortisol; Hypersecretion
- Trial name
- RESCUE (NCT05307328)
- Testing
- SPI-62
- Where
- 12 sites in United States, Bulgaria and 1 more
- Volunteers
- 26 people
- Sponsor
- Sparrow Pharmaceuticals